Stockreport

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant De...

Atai Beckley N.V - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinica [Read more]